Clinical significance of CD38 and CD101 expression in PD‑1+CD8+ T cells in patients with epithelial ovarian cancer

Zhou,Jian; Wang,Wenting; Liang,Zhiqing; Ni,Bing; He,Wei; Wang,Dan

doi:10.3892/ol.2020.11580

Clinical significance of CD38 and CD101 expression in PD‑1+CD8+ T cells in patients with epithelial ovarian cancer

Authors:
- Jian Zhou
- Wenting Wang
- Zhiqing Liang
- Bing Ni
- Wei He
- Dan Wang
View Affiliations

Affiliations: Department of Pathophysiology, College of High Altitude Military Medicine, Third Military Medical University, Chongqing 400038, P.R. China, Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: April 28, 2020 https://doi.org/10.3892/ol.2020.11580
Pages: 724-732
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies using mouse liver tumor models have indicated that coexpression of CD38 and CD101 in programmed cell death‑1 (PD‑1)+CD8+ T cells may reflect fixed dysregulation of CD8+ T cells and thus indicate a poor response to anti‑PD‑1 immunotherapy. However, whether CD38 and CD101 expression in PD‑1+CD8+ T cells can predict the clinical status and efficacy of chemotherapy for various cancer types, including ovarian cancer (OC), remains unclear. In the present study, peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll‑Hypaque gradient centrifugation from 96 fresh samples from healthy adult volunteers and patients with epithelial OC, aged 55.21±9.91 years. Additionally, tumor‑infiltrating lymphocytes (TILs) were separated using a combination of mechanical, chemical and enzymatic digestion from fresh surgically removed tumor tissues from 15 patients with epithelial OC. The expression of CD38 and CD101 in PD‑1+CD8+ T cells or TILs was detected by flow cytometry or immunofluorescence (IF) staining, respectively. The association between the level of CD38/CD101 expression and clinicopathological parameters or postoperative chemotherapy in patients with OC was statistically analyzed. The levels of CD38/CD101‑coexpressing PD‑1+CD8+ T cells were significantly increased in PBMCs and TILs of patients with OC compared with those of healthy volunteers. The frequency of PD‑1+CD38+CD101+CD8+ T cells among the total PD‑1+CD8+ T cell subpopulation was negatively associated with clinical stage, lymph node metastasis and postoperative chemotherapy prognosis in patients with OC. Furthermore, IF staining confirmed colocalization of CD38 and CD101 on the majority of TILs in OC tissues. Thus, the present study suggests that coexpression of CD38 and CD101 in peripheral PD‑1+CD8+ T cells and TILs may serve as a new indicator for diagnosis and treatment efficacy in patients with epithelial OC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Miller EM, Tymon-Rosario J, Strickler HD, Xie X, Xue X, Kuo DYS, Makhija SK and Nevadunsky NS: Racial differences in survival from epithelial ovarian cancer are associated with stage at diagnosis and use of neoadjuvant therapy: A 10-year single-institution experience with a racially diverse urban population. Int J Gynecol Cancer. 28:749–756. 2018. View Article : Google Scholar : PubMed/NCBI
3	Dong X, Men X, Zhang W and Lei P: Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer. 51 (Suppl 3):e72–e76. 2014. View Article : Google Scholar : PubMed/NCBI
4	Santoiemma PP and Powell DJ Jr: Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 16:807–820. 2015. View Article : Google Scholar : PubMed/NCBI
5	Prosser ME, Brown CE, Shami AF, Forman SJ and Jensen MC: Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 51:263–272. 2012. View Article : Google Scholar : PubMed/NCBI
6	Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I and Ascierto PA: Cancer treatment with anti-PD-1/PD-L1 agents: Is PD-L1 expression a biomarker for patient selection? Drugs. 76:925–945. 2016. View Article : Google Scholar : PubMed/NCBI
7	Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, et al: Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 45:389–401. 2016. View Article : Google Scholar : PubMed/NCBI
8	Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, et al: Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 545:452–456. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rådestad E, Klynning C, Stikvoort A, Mogensen O, Nava S, Magalhaes I and Uhlin M: Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. 8:e15357302018. View Article : Google Scholar : PubMed/NCBI
10	Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H and Zinkernagel RM: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA. 96:2233–2238. 1999. View Article : Google Scholar : PubMed/NCBI
11	Ada G: The enunciation and impact of Macfarlane Burnet's clonal selection theory of acquired immunity. Immunol Cell Biol. 86:116–118. 2008. View Article : Google Scholar : PubMed/NCBI
12	Reimann J, Böhm W and Schirmbeck R: Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes. Biol Chem Hoppe Seyler. 375:731–736. 1994.PubMed/NCBI
13	Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman GJ, Krogsgaard M and Riley JL: Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA. 110:E2480–E2489. 2013. View Article : Google Scholar : PubMed/NCBI
14	Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G and Escors D: PD1 signal transduction pathways in T cells. Oncotarget. 8:51936–51945. 2017. View Article : Google Scholar : PubMed/NCBI
15	Srinivasan P, Wu X, Basu M, Rossi C and Sandler AD: PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. PLoS Med. 15:e10024972018. View Article : Google Scholar : PubMed/NCBI
16	Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992. View Article : Google Scholar : PubMed/NCBI
17	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
18	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
19	Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2:846–856. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xu-Monette ZY, Zhang M, Li J and Young KH: PD-1/PD-L1 blockade: Have we found the key to unleash the antitumor immune response? Front Immunol. 8:15972017. View Article : Google Scholar : PubMed/NCBI
21	Hellström I, Hellström KE, Pierce GE and Yang JP: Cellular and humoral immunity to different types of human neoplasms. Nature. 220:1352–1354. 1968. View Article : Google Scholar : PubMed/NCBI
22	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
23	Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015. View Article : Google Scholar : PubMed/NCBI
24	Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, Funaro A, Horenstein AL and Malavasi F: CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom. 84:207–217. 2013. View Article : Google Scholar : PubMed/NCBI
25	d'Ettorre G, Ceccarelli G, Serafino S, Giustini N, Cavallari EN, Bianchi L, Pavone P, Bellelli V, Turriziani O, Antonelli G, et al: Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy. J Med Virol. 88:1347–1356. 2016. View Article : Google Scholar : PubMed/NCBI
26	Mao X, Peng L, Liu X, Yang Y, Wang Q, Wang D, Xiao J and Leng J: TLR9 expression is positively correlated with the levels of CD38, HLA-DR and CD95 on peripheral blood mononuclear cells in chronic HBV infected patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:660–665. 2016.(In Chinese). PubMed/NCBI
27	Rivas A, Ruegg CL, Zeitung J, Laus R, Warnke R, Benike C and Engleman EG: V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies. J Immunol. 154:4423–4433. 1995.PubMed/NCBI
28	Soares LR, Tsavaler L, Rivas A and Engleman EG: V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca²⁺ flux and nuclear factor of activated T cell nuclear translocation. J Immunol. 161:209–217. 1998.PubMed/NCBI
29	Gouttefangeas C, Jacquot S, Meffre E, Schmid M, Boumsell L and Bensussan A: Differential proliferative responses in subsets of human CD28+ cells delineated by BB27 mAb. Int Immunol. 6:423–430. 1994. View Article : Google Scholar : PubMed/NCBI
30	Urban N, Mcintosh MW, Andersen M and Karlan BY: Ovarian cancer screening. Hematol Oncol Clin North Am. 17989–1005. (ix)2003. View Article : Google Scholar : PubMed/NCBI
31	Urban N and Drescher C: Current and future developments in screening for ovarian cancer. Womens Health (Lond). 2:733–742. 2006.PubMed/NCBI
32	Kafali H, Artunc H and Erdem M: Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 275:175–177. 2007. View Article : Google Scholar : PubMed/NCBI
33	Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15 (Suppl 3):S274–S281. 2005. View Article : Google Scholar
34	Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 99:267–277. 2005. View Article : Google Scholar : PubMed/NCBI
35	Zhao T and Hu W: CA125 and HE4: Measurement tools for ovarian cancer. Gynecol Obstet Invest. 81:430–435. 2016. View Article : Google Scholar : PubMed/NCBI
36	Xi QP, Pu DH and Lu WN: Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. Eur Rev Med Pharmacol Sci. 21:4536–4541. 2017.PubMed/NCBI
37	Zhang M, Yang J, Zhou J, Gao W, Zhang Y, Lin Y, Wang H, Ruan Z and Ni B: Prognostic values of CD38⁺CD101⁺PD1⁺CD8⁺ T cells in pancreatic cancer. Immunol Invest. 48:466–479. 2019. View Article : Google Scholar : PubMed/NCBI
38	Kumari S: Serum biomarker based algorithms in diagnosis of ovarian cancer: A review. Indian J Clin Biochem. 33:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
39	Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin BD, Fu HT and Zhong RQ: Diagnostic value of osteopontin in ovarian cancer: A meta-analysis and systematic review. PLoS One. 10:e01264442015. View Article : Google Scholar : PubMed/NCBI
40	Wei R, Wong JPC and Kwok HF: Osteopontin-a promising biomarker for cancer therapy. J Cancer. 8:2173–2183. 2017. View Article : Google Scholar : PubMed/NCBI
41	Han X, Wang W, He J, Jiang L and Li X: Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett. 17:2592–2598. 2019.PubMed/NCBI